[go: up one dir, main page]

TW200900417A - Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose - Google Patents

Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose Download PDF

Info

Publication number
TW200900417A
TW200900417A TW097106815A TW97106815A TW200900417A TW 200900417 A TW200900417 A TW 200900417A TW 097106815 A TW097106815 A TW 097106815A TW 97106815 A TW97106815 A TW 97106815A TW 200900417 A TW200900417 A TW 200900417A
Authority
TW
Taiwan
Prior art keywords
formula
compound
solvent
deoxy
group
Prior art date
Application number
TW097106815A
Other languages
Chinese (zh)
Inventor
Jae-Heon Lee
Gha-Seung Park
Weon-Ki Yang
Jin-Hee Kim
Chul-Hyun Park
Yong Hoon An
Chang Ju Choi
Young Kil Chang
Gwan Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of TW200900417A publication Critical patent/TW200900417A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00Preparation of derivatives of starch

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention discloses a method for preparing highly pure tri-O-acetyl-5-deoxy-β -D-ribofuranose which comprises a highly stereoselective acetylation step of 1-methylacetonide, and the pure β -anomer thus obtained can be advantageous used for preparing capecitabine.

Description

200900417 九、發明說明: L 明所屬領】 發明領域 ~0'乙酸-5-去氧- 瘤達的中間物。 本發明關於一種立體選擇性製備與分離三 5 /3 -D-呋喃核糖的方法,該呋喃核糖用作製備戴 發明背景 截瘤達,(一具有呋喃核糖主鏈的核苦), J,為—抗腫瘤 劑,經口服投予該劑以治療轉移性乳癌與直腸痒並具有 10其中連接在吱喃核糖的位置1上的5-氟胞嘧D定部分具有 位向的下列所示之立體化學結構:200900417 IX, invention description: L Ming belongs to the field of invention] ~0 'acetate-5-deoxy-tumor intermediate. The invention relates to a method for stereoselectively preparing and isolating tris/5-D-ribofuranose, which is used for preparing the background of the invention, (a nuclear bitter with a ribofuranose backbone), J, An antitumor agent, which is administered orally to treat metastatic breast cancer and rectal itching and has a 10-fluorocytosine moiety in which the 5-fluorocytosine moiety attached to position 1 of the glucopyranose has a orientation as shown below. Chemical structure:

如美國專利第5,453,497號中所述,截瘤達可藉由將三 -0-乙醯-5-去氧j-D-吱喃核糖以氟胞嘧啶糖化及接著使 15所得產物接受胺甲醯基化反應與水解而製備,如反應流程 (A)中所示。 反應流裎ίΑ、As described in U.S. Patent No. 5,453,497, the nodulation can be achieved by saccharification of trioxo-5-deoxyjD-pyridose ribose with fluorocytosine followed by accepting the amine for mercaptolation of the product obtained by 15 The reaction is prepared by hydrolysis and is shown in the reaction scheme (A). Reaction flow 裎 Α,

(V) 5 (I) 200900417 上述所使用的原料,式⑴之三_〇_乙酿-5-去氧_召七_„夫 。南核糖係根據在美國專利第4,340,729號中所述之方法製 備,如反應流程⑼中所示。特別地,⑴將式(1¥)化合物水 解’以獲得式(III)之三元醇化合物;(ii)在吼咬中使用乙酸 5酐將式(ΠΙ)之三元醇化合物乙醯化,以獲得式(II)之三_〇_ 乙醯-5·•去氧呋喃核糖,其為關於在位置1上的乙醯基之 /5 _/α-變旋異構物混合物;(iii)使反應混合物接受真空蒸 顧’以純化/3-/α-變旋異構物混合物;及(iv)將式(I)之卢_ 變旋異構物自該混合物分離。 10 反應流程(B)(V) 5 (I) 200900417 The above-mentioned raw materials, the formula (1) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Preparation, as shown in the reaction scheme (9). Specifically, (1) hydrolyzing a compound of the formula (1) to obtain a triol compound of the formula (III); (ii) using acetic anhydride 5 in a bite (将) The triol compound is acetylated to obtain the ternary oxime of the formula (II) _ 〇 醯 · · 去 去 去 , , , , 关于 关于 关于 关于 关于 在 在 在 在 在a mixture of spinning isomers; (iii) subjecting the reaction mixture to vacuum distillation to purify the /3-/α-raceomer mixture; and (iv) the _ _ _ _ Separation from the mixture. 10 Reaction Scheme (B)

再者,在吡啶中三元醇化合物以乙酸酐來獲得三_〇_乙 醯-5-去氧-D-呋喃核糖的乙醯化反應也被敘述於其他的報 導中[J. Med· Chem·,2000,vol. 43,pp 2566-2574]、 15 [Carbohydrate Research, 2003,vol. 338, pp 303-306]、 [Nuclear Medicine and Biology, 2004, vol. 31,pp 1033-1041] 及[J· Am. Chem· Soc.,1957, vol. 79, pp 5534-5540]。 然而,上述製備三-O-乙醯-5-去氧-D-呋喃核糖的方法 由於使用吡啶作為溶劑而受到各種問題的牵制:在反應之 20 後的整理量非常大且需要複雜的多步驟整理程序;變旋 異構物形成的選擇性低,三-0-乙醯-5-去氧-D-呋喃核糖產 物的/5-/α -變旋異構物之比不超過3 : 1至3.5 : 1 ;及由於 200900417 有相對大量的α -變旋異構物存在,藉由再結晶作用將所欲 之式(I)之召-變旋異構物自/3-/α-變旋異構物混合物分離 有困難,而且只得到約35至40%之產率。 因此,本發明企圖發展一種製備三-〇-乙醯-5-去氧-/5 5 -D-呋喃核糖的改進方法,並發現/3-/α-變旋異構物之比可 藉由在乙醯化反應期間使用烷胺或環胺鹼類取代吡啶而顯 著地改進。 【發明内容】 發明概要 10 據此,本發明的一目的係提供一種製備具有高的/5-變 旋異構物比之二_〇_乙酿-5-去氧-A -D-n夫喃核糖的方法。本 發明的另一目的係提供一種將三-0-乙醯-5-去氧-D-呋喃核 糖的純yS-變旋異構物自其之/5-/α-變旋異構物混合物分 離的簡單且容易的方法。 15 根據本發明的一個觀點,其係提供一種製備式⑴之三 -0-乙酿-5-去氧-卢-D-a夫喃核糖的方法,其包含步驟. ⑴在烷胺或環胺的存在下於有機溶劑中進行式(III)化 合物與乙酸酐的反應,以獲得式(II)化合物;及 (ii)藉由使用溶劑及反溶劑的再結晶作用分離式⑴化 20 合物與式(II)化合物: 200900417Furthermore, the acetylation reaction of tris-ol compounds in pyridine with acetic anhydride to obtain tris-oxime-5-deoxy-D-ribofuranose has also been described in other reports [J. Med·Chem ·, 2000, vol. 43, pp 2566-2574], 15 [Carbohydrate Research, 2003, vol. 338, pp 303-306], [Nuclear Medicine and Biology, 2004, vol. 31, pp 1033-1041] and [ J. Am. Chem. Soc., 1957, vol. 79, pp 5534-5540]. However, the above process for preparing tris-O-acetam-5-deoxy-D-ribofuranose is hampered by various problems due to the use of pyridine as a solvent: the amount of finishing after the reaction 20 is very large and requires complicated multi-steps. Finishing procedure; the selectivity of the formation of the racemic isomer is low, the ratio of the /5-/α-raceomer of the trioxo-5-deoxy-D-ribofuranose product does not exceed 3:1 To 3.5:1; and due to the relatively large amount of α-raceomers present in 200900417, the desired formulae of the formula (I) is changed from /3-/α- by recrystallization. Separation of the mixture of isomers is difficult and only yields from about 35 to 40% are obtained. Accordingly, the present invention seeks to develop an improved process for the preparation of tris-indole-5-deoxy-5/5-D-ribofuranose and finds that the ratio of /3-/[alpha]-helical isomers can be Significant improvement is achieved by the use of alkylamines or cyclic amine bases in place of pyridine during the oximation reaction. SUMMARY OF THE INVENTION According to the present invention, it is an object of the present invention to provide a bismuth-5-deoxy-A-Dn ribose ribose having a high ratio of /5-rotational isomers. Methods. Another object of the present invention is to provide a pure yS-raceomer of trioxo-5-deoxy-D-ribofuranose from its/5-/α-spinning isomer mixture A simple and easy way to separate. According to one aspect of the present invention, there is provided a process for the preparation of the trioxo-5-deoxy-lu-Da-flana ribose of the formula (1), which comprises the steps. (1) in the presence of an alkylamine or a cyclic amine The reaction of the compound of the formula (III) with acetic anhydride in an organic solvent to obtain the compound of the formula (II); and (ii) the separation of the compound (1) and the formula by recrystallization using a solvent and an antisolvent ( II) Compound: 200900417

L實施方式3 較佳實施例之詳細說明 根據本發明用於立體選擇性乙醯化反應及分離/5 -變 5 旋異構物的方法係顯示於流程(C)中。 流程(C)L. Embodiment 3 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A method for stereoselective acetamylation reaction and separation of /5-dependent spiromers according to the present invention is shown in Scheme (C). Process (C)

(IV) (ill) (II) (I) 特別地,式(IV)之甲基縮丙酮化物(methylacetonide)化 合物係藉由美國專利第4,340,729號中所述之慣例方法去保 10 護,以獲得式(III)之三元醇化合物,其具有約1 : 1至2 : 1 的α -對/5 -之比的α -//3 -變旋異構物混合物型式。變旋異構 物可視需要藉由於下一步驟中使用的管柱層析法分離。式 (IV)之曱基縮丙酮化物化合物可藉由美國專利第4,340,729 號中所述之方法輕易地製備。 15 在乙醯化式(III)之三元醇化合物的步驟中,可使用以 式(III)化合物為基準計3莫耳當量或更多的量之烷胺或環胺 200900417 代替如先前技藝所教示的使用純α比咬作為溶劑,以達成三 元醇化合物與乙酸奸的南立體選擇性反應.產物式(II)之 三-0-乙醯-5-去氧呋喃核糖包括一顯著的高万-變旋異 構物含量,α-對/5-變旋異構物之比為1 : 10或更高。該富 5含々_變旋異構物之產物可接受使用溶劑或反溶劑的再結 晶作用,以獲得具有99.5%及更高的高產率之南純度的式(I) 之/3 -變旋異構物。 如上所述,不像使用過量純吡啶作為溶劑的慣例方 法,本發明的方法得到具有高的冷-變旋異構物含量之三 10乙醯-5-去氧-D_呋喃核糖,該方法係使用等量的烷胺或環胺 與有機溶劑一起進行。因此’在反應之後的整理過程大為 簡化。亦即,純三-0-乙醯-5-去氧-石-D-咬喃核糖可從乙醯 化反應混合物回收,並可以使用溶劑及反溶劑的簡單式再 詰晶作用輕易地獲得80%及更高的高產率,而不進行在慣 15 例方法中所使用的高真空蒸餾作用。 在根據本發明的乙酿化反應中所使用的有機溶劑可選 自由四氫呋喃、乙腈、二氣甲烷 '氣仿、二溴乙烷 '二氯 乙炫、乙酸乙酿、甲苯及其混合物所組成的群組中,以二 氯甲炫較佳。 20 在本發明所使用的烷胺或環胺可選自由三乙胺、正_三 丁胺、二環己胺、四甲基乙二胺、二異丙基乙胺、N_甲基 鳴淋及其混合物所組成的群組,以三乙胺較佳。 根據所使用的烷胺或環胺種類,超越α-變旋異構物的 變旋異構物之選擇性從至少1〇 :丨增加至15 :丨,其中三 200900417 乙胺的使用較佳,而°辰σ定無效。 在本發明中,以式(III)化合物為基準計,烷胺或環胺 的量可為3至12莫耳當量,以4至5莫耳當量較佳。 根據本發明的乙醯化反應可在10至50°C下,以5至25 5 °C較佳,進行6至24小時。 在乙酿化反應之後,由於其高的点-變旋異構物含量而 以一固體獲得式(II)之三-0-乙醯-5-去氧-D-呋喃核糖,不像 使用吡啶的慣例方法所獲得的產物為油或半固體。 以本發明的乙醯化方法所獲得的式(II)之三-0-乙醯-5-10 去氧-D-呋喃核糖主要由所欲之yS-變旋異構物所組成,α-變旋異構物含量僅6至9%。為了從其獲得純的/5-變旋異構 物,α-變旋異構物可藉由依照任何慣例方法的再結晶作用 而移除。例如,純的/5 -變旋異構物可藉由將反溶劑加入由 將該變旋異構物混合物溶解在一適當的溶劑中所獲得的溶 15 液中,過濾以移除含有變旋異構物的過濾物,及收集成 為固體的/5-變旋異構物而輕易地分離。 在再結晶作用中所使用的適當溶劑可為一極性有機溶 劑,其係選自由甲醇、乙醇、丙醇、異丙醇、正丁醇、丙 酮、乙腈、四氫呋喃、氯仿、二氯曱烷、乙酸乙酯、二乙 20 醚及其混合物所組成的群組,以異丙醇較佳。在再結晶作 用中所使用的反溶劑可為一非極性有機溶劑,其係選自由 正己烧、庚烧、辛烧、壬烧、石油醚、異丙醚及其混合物 所組成的群組,或可為水,以正己烷或水較佳。 再結晶作用可在-60至30°C下進行,以-10至5°C較佳, 10 200900417 並且溶劑及反溶劑量,以式(II)之三_〇_乙酿_5_去氧七 核糖為基準計,可分別為2至5倍(體積/重量)及5至^ 積/重量)。 σ(體 在再結晶作用之後所獲得的/5-變旋異構物具有—至 5少99.5%之純度,α_變旋異構物含量少於〇5%。 如上所述,以立體選擇性製備式⑴之三乙酿_5_去氧 -/3-D·咬喃核糖的本發明方法,與慣例的方法相比,顯干出 顯著改進的立體選擇性,且與以慣例的方法所獲得的小於 35至40%之產率減,得到至少75%的高產率。 、 1〇下列的實例意欲進—步說明本發明,而非限制其範圍。 在下列的實例中,在式⑴化合物的情況中,GC(氣相 層析法)係使用氰丙基笨基聚石夕氧烧管柱(内徑:〇 32毫米, 長度60公尺’厚度:丨8微米)(例如,db 624)操作,並且試 驗溶液係藉由將⑽毫克式⑴化合物溶解在二甲基亞石風 15中,以製成25毫升溶液而製備。 趣:式(II)之三-〇乙聽_5·去氧如夫仙糖的立鍾選擇 性製備作用(IV) (ill) (II) (I) In particular, the methylacetonide compound of the formula (IV) is protected by the conventional method described in U.S. Patent No. 4,340,729. A triol compound of formula (III) having a ratio of a-//3-isomer mixture of about 1:1 to 2:1 ratio of α-pair/5-. The racemic isomers can be separated by column chromatography as used in the next step, as desired. The fluorenyl acetonide compound of the formula (IV) can be easily prepared by the method described in U.S. Patent No. 4,340,729. In the step of acetylating the triol compound of the formula (III), an alkylamine or a cyclic amine 200900417 in an amount of 3 mole equivalents or more based on the compound of the formula (III) may be used instead of the prior art. The teaching uses a pure alpha ratio bite as a solvent to achieve a south stereoselective reaction of a triol compound with acetic acid. The product of formula (II) tris-0-acetam-5-deoxyribofuranose includes a significant high The ratio of the osmolality to the α-p-/5-stacked isomer is 1:10 or higher. The product of the cerium-rich vortexomer can be subjected to recrystallization using a solvent or an anti-solvent to obtain a /3 - vortex of the formula (I) having a high purity of 99.5% and higher in south purity. Isomer. As described above, unlike the conventional method using an excess of pure pyridine as a solvent, the method of the present invention obtains tris10-acetam-5-deoxy-D-ribofuranose having a high cold-rotational isomer content. The use of an equivalent amount of an alkylamine or a cyclic amine is carried out together with an organic solvent. Therefore, the finishing process after the reaction is greatly simplified. That is, pure tris-O-acetam-5-deoxy-stone-D-arabose can be recovered from the acetamidine reaction mixture, and can be easily obtained by simple recrystallization of solvent and antisolvent. High yields of % and higher without the high vacuum distillation used in the conventional 15 methods. The organic solvent used in the brewing reaction according to the present invention may be selected from the group consisting of tetrahydrofuran, acetonitrile, di-methane methane, dibromoethane, dichloroethane, acetic acid, toluene and mixtures thereof. Among the groups, it is preferred to use dichloromethane. 20 The alkylamine or cyclic amine used in the present invention may be selected from triethylamine, n-tributylamine, dicyclohexylamine, tetramethylethylenediamine, diisopropylethylamine, N-methylamine A group consisting of a mixture thereof and triethylamine is preferred. Depending on the alkylamine or cyclic amine species used, the selectivity of the racemic isomer beyond the α-helical isomer increases from at least 1 〇:丨 to 15:丨, of which three 200900417 ethylamine is preferred for use. And ° σ σ is invalid. In the present invention, the amount of the alkylamine or cyclic amine may be from 3 to 12 mol equivalents, preferably from 4 to 5 mol equivalents, based on the compound of the formula (III). The acetylation reaction according to the present invention can be carried out at 10 to 50 ° C, preferably 5 to 25 5 ° C, for 6 to 24 hours. After the B-stuffing reaction, the tri-O-acetyl-5-deoxy-D-ribofuranose of the formula (II) is obtained as a solid due to its high point-rotational isomer content, unlike the use of pyridine. The product obtained by the conventional method is oil or semi-solid. The trioxo-5-10-deoxy-D-ribofuranose of the formula (II) obtained by the acetylation method of the present invention is mainly composed of the desired yS-raceomer, α- The content of the spinning isomer is only 6 to 9%. In order to obtain a pure/5-rotational isomer therefrom, the α-rotation isomer can be removed by recrystallization according to any conventional method. For example, a pure /5-rotational isomer can be removed by adding an anti-solvent to a solution 15 obtained by dissolving the mixture of the rotatory isomers in a suitable solvent. The filtrate of the isomer is easily separated by collecting as a solid/5-. A suitable solvent for use in the recrystallization may be a polar organic solvent selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, acetone, acetonitrile, tetrahydrofuran, chloroform, dichloromethane, acetic acid. The group consisting of ethyl ester, diethyl 20 ether and mixtures thereof is preferably isopropanol. The anti-solvent used in the recrystallization may be a non-polar organic solvent selected from the group consisting of n-hexanol, heptane, cinnabar, teriyaki, petroleum ether, isopropyl ether, and mixtures thereof, or It may be water, preferably n-hexane or water. Recrystallization can be carried out at -60 to 30 ° C, preferably -10 to 5 ° C, 10 200900417 and the amount of solvent and anti-solvent, with the formula (II) _ _ _ _ _ 5 _ deoxygenation Based on the seven-ribose sugar, it can be 2 to 5 times (volume/weight) and 5 to 2 product/weight, respectively. σ (the body of the 5 - mutated isomer obtained after recrystallization has - to less than 99.5% purity, the α_ Cyclone isomer content is less than 〇 5%. As described above, with stereoselection The method of the present invention for preparing the triethyl _5_deoxy-/3-D· tranose ribose of the formula (1) exhibits significantly improved stereoselectivity compared to the conventional method, and in a conventional manner The obtained yield reduction of less than 35 to 40% yields a high yield of at least 75%. The following examples are intended to illustrate the invention without limiting its scope. In the following examples, in the formula (1) In the case of the compound, GC (gas chromatography) is a column of cyanopropyl stupid polyoxygen tube (inner diameter: 〇32 mm, length 60 m' thickness: 丨8 μm) (for example, db 624) Operation, and the test solution was prepared by dissolving (10) mg of the compound of the formula (1) in dimethyl sulphur wind 15 to prepare a 25 ml solution. Interest: Formula (II) 3 - 〇 B listen _ 5 ·Selective preparation of degassing such as vanillin

V^〇h ——.Vr〇At HO 〇H ? \V^〇h ——.Vr〇At HO 〇H ?

AeO OAc 0") (II) (l l)M使用二乙胺作為驗的程序 20 將100公克的甲基-2,3-〇-異亞丙-5-去氧ID-咬鳴核 糖加入500亳升〇·〇2Μ硫酸中,並在8〇至85<^下攪拌2小時。 使溫度下降至45至耽,並在減財移除水,直到總體積 11 200900417 由2/3減少至1/2為止。將500毫升0 02M硫酸加入所得溶液 中,並在80至85。(:下攪拌1小時。使溫度下降至室溫,將所 得溶液以0·2Μ碳酸鈉中和至pH 5.3至5.5,並在減壓下濃 縮。將所得殘餘物懸浮在1,000毫升乙腈中,並將5〇公克無 水硫酸鈉加入其中及攪拌1小時。將所得混合物經由矽藻土 官柱過濾,接著將其以100毫升乙腈清洗,將過濾物及清洗 物合併,並在減壓下濃縮,以移除溶劑。將1,〇〇〇毫升二氯 甲烷及370毫升三乙胺加入所得殘餘物中,同時使溫度維持 在5。(:下,加入235_5毫升乙酸酐及攪拌20小時。在反應完 成之後,將1,000毫升水加入所得反應混合物中,檀拌及將 有機層分離。接著將有機層以1,000毫升數份的丨N HC1、飽 和碳酸氫鈉及食鹽水連續清洗,並接著經無水硫酸鈉乾 垛。將所得有機層在減壓下濃縮,以獲得標題化合物(140.8 公克)。將因此獲得的產物以GC分析,其顯示產物包括1 : 15 U.8之比的α-與石-變旋異構物。 4 NMR (300MHz,CDC13):(泠-變旋異構物)δ 6-〇9(s,1H), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26(q,lH), 2-l〇(s,3H),2.07(s,3H),2.05(s,3H),1.35(d,3H)。 4 NMR (300MHz,CDC13) : ( a -變旋異構物)<5 2〇 6-2l(d,lH), 5.11(dd,lH), 4.8(dd,lH), 4.15 4.20(m,lH), 1970,111),1.92(8,311),1.89(8,311),1.21((1,311)° d-2)當使用三-正丁胺作為鹼的程序 重複(1-1)之最初程序,除了使用5公克甲基-2,3-0-異亞 丙-5-去氧-/5-D-呋喃核糖之外,以獲得三元醇化合物。接 12 200900417 著,將50毫升二氯甲烷及31·6毫升三-正丁胺加入所得殘餘 物中,將11.8毫升乙酸酐緩慢加入其中,並在室溫下攪拌12 小時。在反應完成之後,將50毫升水加入反應混合物中, 攪拌及將有機層分離。接著將有機層以50毫升數份的1N 5 HC1、飽和碳酸氫鈉及食鹽水連續清洗,經無水硫酸納乾燥 及過濾。將所得過濾物在減壓下濃縮,以獲得標題化合物 (7公克)。將因此獲得的產物以GC分析,其顯示產物包括j : 11.2之比的α -與/5 -變旋異構物。 (1-3)當使用四甲基乙二胺作為鹼的程序 10 重複(1-1)之最初程序,除了使用5公克曱基-2,3-〇_異亞 丙-5-去氧-/S-D-呋喃核糖之外,以獲得三元醇化合物。接 著,將50毫升二氯甲烷及20毫升四甲基乙二胺加入所得殘 餘物中,將11.8毫升乙酸酐緩慢加入其中,並在室溫下攪掉 12小時。在反應完成之後,將50毫升水加入反應混合物中, 15攪拌及將有機層分離。接著將有機層以50毫升數份的1N HC1、飽和碳酸氫鈉及食鹽水連續清洗,經無水硫酸鈉乾燥 及過濾。將所得過濾物在減壓下濃縮,以獲得標題化合物 (7公克)。將因此獲得的產物以Gc分析,其顯示產物包括^ : 10.3之比的α-與点-變旋異構物。 20生毯逢^ :當使用吡啶作為有機驗的程序 將5公克甲基-2,3-0-異亞丙_5_去氧_石_D_吱喃核糖加 入25毫升〇.〇2M硫酸中,並在肋至“它下攪拌2小時。使溫 度下降至45至5〇t,並在減壓下移除水,直到總體積由奶 減少至1/2為止。將25毫升〇.〇2M硫酸加入所得溶液中,並 13 200900417 •在80至85°C下攪拌1小時。使溫度下降至室溫,將所得溶液 • 以0.2M碳酸鈉中和至pH 5.3至5.5,並在減壓下濃縮。將所 得殘餘物懸浮在50毫升乙腈中,並將5公克無水硫酸鈉加人 其中及攪拌1小時。將所得混合物經由矽藻土管柱過濾,接 . 5 著將其以5毫升乙腈清洗,將過濾物及清洗物合併,並在減 壓下濃縮。將11.8毫升乙酸酐及25毫升吡啶加入所得殘餘物 中,並攪拌12小時。在反應完成之後’將1〇〇毫升水加入其 中’擾摔1小時’並將所得溶液以1 〇〇毫升二氯甲烧萃取。 將有機層以100毫升數份的IN HC1清洗三次,然後以100毫 10升數份的飽和碳酸氫鈉及食鹽水連續清洗。將有機層經無 水硫酸鈉乾燥及過濾。將所得過濾物在減壓下濃縮,以獲 得標題化合物(6.8公克)。將因此獲得的油狀產物wGc分AeO OAc 0") (II) (ll) M using diethylamine as a procedure for the test 20 Add 100 grams of methyl-2,3-indole-5-deoxy ID-bisting ribose to 500 亳Rise in Μ2Μ sulfuric acid and stir for 2 hours at 8〇 to 85<^. Decrease the temperature to 45 to 耽 and remove the water in the loss of money until the total volume 11 200900417 is reduced from 2/3 to 1/2. 500 ml of 0 02 M sulfuric acid was added to the resulting solution at 80 to 85. (The mixture was stirred for 1 hour. The temperature was lowered to room temperature, the resulting solution was neutralized to pH 5.3 to 5.5 with 0. 2 Μ sodium carbonate, and concentrated under reduced pressure. The obtained residue was suspended in 1,000 ml of acetonitrile. 5 gram of anhydrous sodium sulfate was added thereto and stirred for 1 hour. The resulting mixture was filtered through a column of celite, and then washed with 100 ml of acetonitrile, and the filtrate and washings were combined and concentrated under reduced pressure. To remove the solvent, 1. 〇〇〇ml of dichloromethane and 370 ml of triethylamine were added to the residue while maintaining the temperature at 5. (:, 235_5 ml of acetic anhydride was added and stirred for 20 hours. After the reaction was completed, 1,000 ml of water was added to the obtained reaction mixture, and the organic layer was separated, and then the organic layer was successively washed with 1,000 ml portions of 丨N HCl, saturated sodium hydrogencarbonate and brine, and then Drying over anhydrous sodium sulfate. The obtained organic layer was concentrated under reduced pressure to give the title compound (140.8 g). The product thus obtained was analyzed by GC, which showed that the product included a ratio of 1:15 U.8. With stone-variation Isomers. 4 NMR (300MHz, CDC13): (泠-Zero isomers) δ 6-〇9(s,1H), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26( q,lH), 2-l〇(s,3H),2.07(s,3H),2.05(s,3H),1.35(d,3H). 4 NMR (300MHz, CDC13) : ( a - Structure) <5 2〇6-2l(d,lH), 5.11(dd,lH), 4.8(dd,lH), 4.15 4.20(m,lH), 1970,111),1.92(8,311), 1.89 (8, 311), 1.21 ((1, 311) ° d-2) The initial procedure for repeating (1-1) when using tri-n-butylamine as the base, except for the use of 5 gram methyl-2,3-0- In addition to propion-5-deoxy-/5-D-ribofuranose, a triol compound is obtained. In 12200900417, 50 ml of dichloromethane and 31.6 ml of tri-n-butylamine are added to the residue. 11.8 ml of acetic anhydride was slowly added thereto, and stirred at room temperature for 12 hours. After the reaction was completed, 50 ml of water was added to the reaction mixture, stirred and the organic layer was separated. Then the organic layer was added in 50 ml portions. 1N 5 HCl, saturated sodium hydrogencarbonate and brine were washed successively, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the title compound. The product thus obtained was analyzed by GC, which showed that the product included α- and /5-raceomers of a ratio of j: 11.2. (1-3) When tetramethylethylenediamine was used as a base Procedure 10 The initial procedure of (1-1) was repeated except that 5 g of fluorenyl-2,3-indole-5-deoxy-/SD-ribofuranose was used to obtain a triol compound. Next, 50 ml of dichloromethane and 20 ml of tetramethylethylenediamine were added to the residue, and 11.8 ml of acetic anhydride was slowly added thereto, and stirred at room temperature for 12 hours. After the reaction was completed, 50 ml of water was added to the reaction mixture, 15 was stirred and the organic layer was separated. The organic layer was successively washed with 50 ml portions of 1N HCl, saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate and filtered. The obtained filtrate was concentrated under reduced pressure to give the title compound (7 g). The product thus obtained was analyzed by Gc, which showed that the product included the α-and-dot-spin isomer of the ratio: 10.3. 20 raw carpets ^: When using pyridine as an organic test procedure, add 5 grams of methyl-2,3-0-isopropylene _5_deoxy_stone_D_pyranose to 25 ml of 〇.〇2M sulfuric acid Medium, and in the ribs to "It is stirred for 2 hours. Let the temperature drop to 45 to 5 〇t, and remove the water under reduced pressure until the total volume is reduced from milk to 1/2. 25 ml 〇.〇 2M sulfuric acid was added to the resulting solution, and 13 200900417 • Stir at 80 to 85 ° C for 1 hour. The temperature was lowered to room temperature, and the resulting solution was neutralized with 0.2 M sodium carbonate to pH 5.3 to 5.5, and decompressed. The residue was suspended in 50 ml of acetonitrile, and 5 g of anhydrous sodium sulfate was added thereto and stirred for 1 hour. The resulting mixture was filtered through a celite column, and then washed with 5 ml of acetonitrile. The filtrate and the washings were combined and concentrated under reduced pressure. 11.8 ml of acetic anhydride and 25 ml of pyridine were added to the residue and stirred for 12 hours. After the reaction was completed, '1 ml of water was added thereto' Spoiled for 1 hour' and extracted the resulting solution with 1 〇〇 ml of methylene chloride. The organic layer was 100 mM. Several portions of IN HC1 were washed three times, and then washed successively with 100 ml of a portion of saturated sodium hydrogencarbonate and brine. The organic layer was dried over anhydrous sodium sulfate and filtered. The title compound (6.8 g). The oily product wGc thus obtained

趣I變旋異構物(式(1)之三_〇_己殖_5_去氧j_D咬鳴 15 核糖)的選擇性結晶作用Selective crystallization of the I-spinning isomer (formula (1) _ _ _ _ _ _ 5 _ deoxy j_D gnash 15 ribose)

份接受如下述之再結晶作用。 20 (2-1) 醇中, 將28公克α/石-變旋異構物混合物溶解在獅升異丙 醇中,亚將168毫升己烧逐滴加入其中。將所得溶液在 14 200900417 。(:下經3小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.9公克,總產率:79·5%)。The fractions were subjected to recrystallization as described below. 20 (2-1) In the alcohol, 28 g of the α/rock-raceomer mixture was dissolved in lion isopropyl alcohol, and 168 ml of hexane was added dropwise thereto. The resulting solution was at 14 200900417. (: The title compound was obtained (31.9 g, total yield: 79.5%).

熔點:65-66°C /3 變旋異構物含量:99.6%( α -變旋異構物含量:0.1 %) 5 4 NMR (300MHz,CDC13) : ( /3 -變旋異構物)5 6.09(s,lH), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26(q,lH), 2.10(s,3H), 2.07(s,3H), 2.05(s,3H), 1.35(d,3H)。 (2-2) 將28公克α/冷-變旋異構物混合物溶解在56毫升異丙 10 醇中,並將168毫升己烷逐滴加入其中。將所得溶液在0至5 °C下經3小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.0公克,總產率:76_4%)。 /3-變旋異構物含量:99.7%(α-變旋異構物含量:0.05%) 熔點及1H-NMR數據與以實例2-1中所獲得的該等相同。 15 (2-3) 將28公克α//3 -變旋異構物混合物溶解在56毫升異丙 醇中,並將168毫升蒸餾水逐滴加入其中。將所得溶液在5 °C下經7小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.3公克,總產率:77.4%)。 20 石-變旋異構物含量:99.5%( α -變旋異構物含量:0.1 %) 熔點及1H-NMR數據與以實例2-1中所獲得的該等相同。 (2-4) 將28公克〇:/召-變旋異構物混合物溶解在56毫升異丙 醇中,並將112毫升蒸餾水逐滴加入其中。將所得溶液在5 15 200900417 °C下經7小時熟化,並過濾,以獲得成為白色固體的標題化 合物(20.7公克,總產率:75.4%)。 /5-變旋異構物含量:99.6%(α-變旋異構物含量:0.1%) 熔點及1Η - N M R數據與以實例2 -1中所獲得的該等相同。 5 (2-5) 將28公克α//3 -變旋異構物混合物溶解在56毫升二氯 甲烷中,並將168毫升己烷逐滴加入其中。將所得溶液在10 °C下經3小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.1公克,總產率:76.5%)。 10 召-變旋異構物含量:99.5%(α-變旋異構物含量:0.1%) 熔點及1H-NMR數據與以實例2-1中所獲得的該等相同。 比較性實例2 將藉由使用吡啶作為有機鹼所獲得的比較性實例1的6.8 公克變旋異構物混合物(變旋異構物:/5-變旋異構物=1 : 15 3.4)溶解在13.6毫升異丙醇中,並將40.8毫升己烷逐滴加入其 中。將所得溶液在0至5°C下經3小時熟化,並過濾,以獲得 成為乳白色固體的標題化合物(2.5公克,總產率:36.2%)。Melting point: 65-66 ° C /3 Spinal isomer content: 99.6% (α-rotational isomer content: 0.1%) 5 4 NMR (300MHz, CDC13) : ( /3 - torsion isomer) 5 6.09(s,lH), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26(q,lH), 2.10(s,3H), 2.07(s,3H), 2.05(s,3H ), 1.35 (d, 3H). (2-2) A 28 g α/cold-rotation isomer mixture was dissolved in 56 ml of isopropyl alcohol, and 168 ml of hexane was added dropwise thereto. The resulting solution was aged at 0 to 5 °C for 3 hours, and filtered to give the title compound (21.0 g,yield: 76_4%) as white solid. /3-Zero isomer content: 99.7% (α-rotational isomer content: 0.05%) The melting point and 1H-NMR data were the same as those obtained in Example 2-1. 15 (2-3) A mixture of 28 g of the α//3-isomer mixture was dissolved in 56 ml of isopropyl alcohol, and 168 ml of distilled water was added dropwise thereto. The resulting solution was aged at 5 °C for 7 hours, and filtered to give the title compound (21.3 g,j. 20 Stone-rotational isomer content: 99.5% (α-rotational isomer content: 0.1%) The melting point and 1H-NMR data were the same as those obtained in Example 2-1. (2-4) A 28 g 〇:/call-raceomer mixture was dissolved in 56 ml of isopropyl alcohol, and 112 ml of distilled water was added dropwise thereto. The resulting solution was aged at 5 15 200900417 °C for 7 hours, and filtered to give the title compound (20.7 g, <RTIgt; /5-Zero isomer content: 99.6% (α-rotational isomer content: 0.1%) Melting point and 1 Η - N M R data are the same as those obtained in Example 2-1. 5 (2-5) 28 g of the α//3-isomer mixture was dissolved in 56 ml of methylene chloride, and 168 ml of hexane was added dropwise thereto. The resulting solution was aged at 10 °C for 3 hours, and filtered to give the title compound (21.1 g,j. 10 Call-spin isomer content: 99.5% (α-rotation isomer content: 0.1%) The melting point and 1H-NMR data were the same as those obtained in Example 2-1. Comparative Example 2 A 6.8 g of a spinning isomer mixture (spin isomer:/5-rotational isomer = 1: 15 3.4) of Comparative Example 1 obtained by using pyridine as an organic base was dissolved. In 13.6 ml of isopropanol, 40.8 ml of hexane was added dropwise thereto. The resulting solution was aged at 0 to 5 °C for 3 hours, and filtered to give the title compound (2.5 g, m.

熔點:63-65°C /3 -變旋異構物含量:99.0%( α -變旋異構物含量:0.6%) 20 【圖式簡單說明】 (無) 【主要元件符號說明】 (無) 16Melting point: 63-65 ° C /3 - Variable isomer content: 99.0% (α - Cyclone content: 0.6%) 20 [Simple description of the diagram] (None) [Key component symbol description] (None ) 16

Claims (1)

200900417 十、申請專利範圍: 1. 一種製備式(I)之三-0-乙醯-5-去氧-/3 -D-呋喃核糖的方 法,其包含步驟: ⑴在烷胺或環胺的存在下於有機溶劑中進行式(III) 化合物與乙酸酐的反應,以獲得式(II)化合物;及 (ii)藉由使用溶劑及反溶劑的再結晶作用分離式(I) 化合物與式(II)化合物:200900417 X. Patent application scope: 1. A method for preparing trioxo-5-deoxy-/3-D-ribofuranose of formula (I), comprising the steps of: (1) in an alkylamine or a cyclic amine The reaction of the compound of the formula (III) with acetic anhydride in an organic solvent to obtain the compound of the formula (II); and (ii) the separation of the compound of the formula (I) and the formula by recrystallization using a solvent and an antisolvent II) Compound: 2.如申請專利範圍第1項之方法,其中在步驟(i)中所使用 的該烷胺或環胺係選自於由三乙胺、正-三丁胺、二環 己胺、四甲基乙二胺、二異丙基乙胺、N-甲基嗎啉及其2. The method of claim 1, wherein the alkylamine or cyclic amine used in the step (i) is selected from the group consisting of triethylamine, n-tributylamine, dicyclohexylamine, and tetramethyl Ethylenediamine, diisopropylethylamine, N-methylmorpholine and 3. 如申請專利範圍第2項之方法,其中該烷胺或環胺的量 以式(III)化合物為基準係從3至12莫耳當量為範圍。 4. 如申請專利範圍第1項之方法,其中在步驟(ii)中所使用 的該溶劑係選自於由甲醇、乙醇、丙醇、異丙醇、正丁 醇、丙酮、乙腈、四氫呋喃、氯仿、二氯曱烷、乙酸乙 酯、二乙醚及其混合物所組成的群組。 17 200900417 5. 如申請專利範圍第1項之方法,其中在步驟(ii)中所使用 的該反溶劑係選自於由正己烷、庚烷、辛烷、壬烷、石 油醚、異丙醚、水及其混合物所組成的群組。 6. 如申請專利範圍第4或5項之方法,其中該溶劑為異丙醇 及該反溶劑為正己炫或水。 18 200900417 七、指定代表圖: (一)本案指定代表圖為:第( )圖。(無) ' (二)本代表圖之元件符號簡單說明: 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式:3. The method of claim 2, wherein the amount of the alkylamine or cyclic amine ranges from 3 to 12 mole equivalents based on the compound of formula (III). 4. The method of claim 1, wherein the solvent used in the step (ii) is selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, acetone, acetonitrile, tetrahydrofuran, A group consisting of chloroform, dichlorodecane, ethyl acetate, diethyl ether, and mixtures thereof. The method of claim 1, wherein the anti-solvent used in the step (ii) is selected from the group consisting of n-hexane, heptane, octane, decane, petroleum ether, and isopropyl ether. , a group of water and its mixture. 6. The method of claim 4, wherein the solvent is isopropyl alcohol and the anti-solvent is hexamethylene or water. 18 200900417 VII. Designated representative map: (1) The representative representative of the case is: ( ). (None) ' (2) A brief description of the symbol of the representative figure: 8. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention:
TW097106815A 2007-02-28 2008-02-27 Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose TW200900417A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070020336A KR100908363B1 (en) 2007-02-28 2007-02-28 Stereoselective preparation method of tri-O-acetyl-5-deoxy-β-D-ribofuranose and separation method thereof

Publications (1)

Publication Number Publication Date
TW200900417A true TW200900417A (en) 2009-01-01

Family

ID=39721406

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097106815A TW200900417A (en) 2007-02-28 2008-02-27 Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose

Country Status (4)

Country Link
KR (1) KR100908363B1 (en)
AR (1) AR065305A1 (en)
TW (1) TW200900417A (en)
WO (1) WO2008105593A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101013312B1 (en) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 Method for preparing capecitabine and method for preparing β-anomer-enhanced trialkyl carbonate compound
EP2210895A1 (en) * 2009-01-27 2010-07-28 F. Hoffmann-La Roche AG Process for the recovery of beta-Acetylfuranoside
CN102344469A (en) * 2011-07-26 2012-02-08 江西科技师范学院 Catalytic synthesis of 1, 2, 3-O-triacetyl-5-deoxy-D-ribofuranose by solid acid SO42-/γ-AL2O3
CN112125939B (en) * 2020-07-16 2024-10-29 中国人民解放军陆军防化学院 Method for preparing high-purity 5-deoxy-D-ribose
CN117229341B (en) * 2023-11-07 2024-02-09 成都苑东生物制药股份有限公司 Capecitabine crystal form I and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
US5252756A (en) 1992-06-22 1993-10-12 Eli Lilly And Company Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs

Also Published As

Publication number Publication date
KR20080079833A (en) 2008-09-02
KR100908363B1 (en) 2009-07-20
WO2008105593A1 (en) 2008-09-04
AR065305A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
CN112020507A (en) Amide compound and method for producing polynucleotide using same
JP2010512365A (en) Method for producing 4&#39;-azidocytidine derivative
JP2000109497A (en) Spirocyclic C-glycoside
CN103517911A (en) Regioselective acylation of rapamycin at the C-42 position
TW200900417A (en) Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose
CN104370932A (en) Process for producing pyripyropene derivative
UA78840C2 (en) Method for the separation of intermediates useful for the preparation of escitalopram
JP2002530423A (en) Novel intermediate, method for producing microlide antibiotics using the same
KR20040021670A (en) Process for the preparation of ribavirin
WO2008087667A1 (en) Preparative process for artesunate from artemisinin
CN103694291B (en) Synthesis method for valrubicin
JP2001521037A (en) Sarcodicin and eleuserobin useful for microtubule stabilization
JP5908479B2 (en) Novel process for producing 9-deoxo-9a-aza-9a-homoerythromycin A in which C-4 &#34;of cladinose ring is modified with an epoxide group
IL180894A (en) 1-alpha-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and processes for the preparation thereof
EA019169B1 (en) A method for the manufacture of highly pure prasugrel
JPH1059994A (en) Method for producing sialic acid derivative
TWI805504B (en) Crystalline form of carboprost tromethamine and preparation process thereof
CN115710209B (en) Method and intermediate for preparing carboprost and carboprost tromethamine, and carboprost tromethamine prepared therefrom
US20090281301A1 (en) Manufacturing Process of 2&#39; ,2&#39; - Difluoronucleoside and Intermediate
TWI861431B (en) Processes and intermediates for the preparations of carboprost and carboprost tromethamine, and carboprost tromethamine prepared therefrom
US7858761B2 (en) 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof
WO2019020067A1 (en) Method for preparing steroid derivative fxr agonist
EP2049558B8 (en) Naphthalene 2-carboxylate derivative useful for synthesizing gemcitabine and a method for preparing the same
JP2003502338A (en) Derivatives of 4&#39;-Demicarosyl-8a-aza-8a-homothyrosine
CN120665128A (en) Compounds, pharmaceutical compositions, kits for capping RNA transcripts, and methods of in vitro transcription